Floatz logo

21 assets in Post-Traumatic Stress Disorder

Therapeutic assets addressing Post-Traumatic Stress Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Post-Traumatic Stress Disorder
Queen's UniversityP4BBB (74)
Sertraline
Post-Traumatic Stress Disorder
Yang I. Pachankis, PhDP4BB (70)
Methylphenidate
Post-Traumatic Stress Disorder
VA Office of Research and DevelopmentP4BB (65)
Duloxetine
Post-Traumatic Stress Disorder
Yang I. Pachankis, PhDP4B (62)
Teonanacatl
Post-Traumatic Stress Disorder
Anthony P KingP2B (60)
Perampanel
Post-Traumatic Stress Disorder
Yale UniversityP2B (58)
Alto-100 Po
Post-Traumatic Stress Disorder
Alto NeuroscienceP2B (57)
3,4-methylenedioxymethamphetamine
Post-Traumatic Stress Disorder
Stephen Robert MarderP2CCC (53)
Apex-002-A02
Post-Traumatic Stress Disorder
Apex Labs Ltd.P2CCC (53)
D-Amphetamine
Post-Traumatic Stress Disorder
Stephen Robert MarderP2CCC (53)
Ibogaine
Post-Traumatic Stress Disorder
Johns Hopkins UniversityP2CCC (53)
Mebufotenin
Post-Traumatic Stress Disorder
Johns Hopkins UniversityP2CCC (53)
Midazolam
Post-Traumatic Stress Disorder
Minneapolis Veterans Affairs Medical CenterP2CCC (53)
Apsolol
Post-Traumatic Stress Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.P1CC (43)
Lithium, Elemental
Post-Traumatic Stress Disorder
Rakitzi, StavroulaP1CC (43)
Prazosin
Post-Traumatic Stress Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc.P1CC (43)
Propofol
Post-Traumatic Stress Disorder
Nyree PennP1CC (43)
sm-001
Post-Traumatic Stress Disorder
Advanced Integrative Medical Science InstituteP1CC (43)
Fluoroethylnormemantine
Post-Traumatic Stress Disorder
ReST TherapeuticsP1CC (41)